(Q35153751)

6 August 2017

1 reference

title

Immune responses in cancer (English)

1 reference

6 August 2017

Jamila K Adam

1

1 reference

6 August 2017

Bharti Odhav

series ordinal

2

1 reference

6 August 2017

Kanti D Bhoola

series ordinal

3

1 reference

6 August 2017

publication date

1 July 2003

1 reference

Pharmacology & Therapeutics

6 August 2017

published in

1 reference

6 August 2017

volume

99

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

113-132

1 reference

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

TNF alpha--a pivotal role in rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

How B and T cells talk to each other

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Perforin and granzyme B expression is associated with severe acute rejection. Evidence for in situ localization in alveolar lymphocytes of lung-transplanted patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Caspases: the executioners of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Cancer vaccines and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Multiple biological activities of human recombinant interleukin 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Treatment of metastatic malignant melanoma with recombinant interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

GM-CSF-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Mammalian caspases: structure, activation, substrates, and functions during apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

1 reference

7 January 2021

Proliferation, cell cycle and apoptosis in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Initiation of Immune Responses by Small Lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Hematopoietic growth factors. Biology and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

'Immune surveillance' without immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Molecular mechanisms of signal transduction in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Vaccination for malignant melanoma: recent developments

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

T-lymphocyte-antigen interactions in transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Apoptosis of tumor cells induced by substances of the circulatory system

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

p53, the cellular gatekeeper for growth and division

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Cancer. DNA damage, deamidation, and death

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

NF-kappaB regulation in the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

To cycle or not to cycle: a critical decision in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Effector mechanisms in allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

VEGF as a mediator of tumor-associated immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

WT1 as a novel target antigen for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Immunotherapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Activators and target genes of Rel/NF-kappaB transcription factors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Macrophage activation by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Bispecific antibodies targeting cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Immune complex-mediated antigen presentation induces tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Fra

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Prostacyclin synthesis induced in vascular cells by interleukin-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Apoptosis signaling in lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Immunotherapy of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

New aspects of natural-killer-cell surveillance and therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

The role of CD8(+) T cells in immune responses to colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

T cell-mediated immune responses in melanoma: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Immunotherapeutic potential of whole tumour cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Signal transduction by lymphocyte antigen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Viral-mediated gene transfer for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Multiple actions of interleukin 6 within a cytokine network

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900056-1

7 January 2021

10.1016/S0163-7258(03)00056-1

Identifiers

DOI

1 reference

6 August 2017

1 reference